November 17, 2005 – Tamiflu was in the news again today, as reports surfaced that the drug caused 12 deaths and 32 psychiatric events among children; Shanghai Sunway Biotech of China, using technology borrowed from Onyx, won Chinese approval for a head and neck cancer drug; the FDA Advisory Committee refused to recommend FDA approval for Certican, a transplant drug, from Novartis despite its benefit; Biomira released positive interim data from a Phase II test of its vaccine for non-small cell lung cancer; Iconix Pharma signed a deal with Lilly giving the big pharma company access to the library of genomic biomarkers; and Biogen Idec discovered a receptor in the central nervous system that may play a crucial role in Parkinson’s disease. Closing at an all-time high, the Centient Biotech 200™ rose a substantial 56 points to 3896.52, a climb of 1.41%. More details...
